Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes

• DOI: 10.1007/s13300-018-0385-5
• Publication Date: 2018-02-27T09:09:50Z
• Authors: Atsutaka Yasui; Ganghyuck Lee; Tetsuaki Hirase; Tatsuroh Kaneko; Stefan Kaspers; Maximilian von Ey...; Tomoo Okamura
• Keywords: Empagliflozin

Empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, ameliorates hyperglycemia in patients with type diabetes (T2D) by inducing sustained glucosuria. Empagliflozin treatment was previously associated transient increase 24-h urine volume Caucasian T2D, however comparable evidence Japanese T2D individuals is scarce. We therefore assessed acute and chronic changes fluid intake empagliflozin T2D.In this randomized, double-blind, placebo-controlled, parallel-group, multiple-dose, 4-week trial, 100 were randomized to receive either 1, 5, 10, or 25 mg placebo once-daily. Changes from baseline at days 27, 28 after the initiation of empagliflozin.The across all groups baseline. Patients treated 10 (i.e., licensed doses Japan) showed significant compared day 1 (mean change baseline: + 0.83, 1.08, 0.29 L/day group, respectively; both p < 0.001 vs. placebo). However, levels 27 (differences vs 0.1 L/day; > 0.05). The study throughout entire period. No events consistent dehydration reported during treatment.Treatment diuresis; however, overall returned towards within 4 weeks treatment. These findings are physiological, adaptive mechanism kidney maintain body balance response SGLT2 inhibitor.NCT00885118.Nippon Boehringer Ingelheim Co., Ltd.